Blogroll
- Ben’s Stem Cell News
- Biosingularity
- Biotech Blog
- Cell WISE
- CellTherapyBlog
- CellTherapyNews
- Fierce Biotech
- Fredrick County, MD Biotech Community
- Hematopoiesis
- IN VIVO blog
- Life Sciences Chronicle
- List of Biotech Conferences
- My Biotech Life
- Partial Immortalization
- Stem Cell Patents
- The Niche
- The Stem Cell
- US PTO
- Venture Beat – Lifesciences
- Wired Blogs – Science
- WordPress.com
Cool Regenmed Jobs
- Biomaterials and Diabetes Scientists at Living Cell Technologies (New Zealand)
- Cell and Tissue Culture Technicians at Pharmacell (ex-US)
- Cell Culture, Bioprocess, Analytical, and Tissue Engineering positions open at Tengion
- Cell Process Development and Production Positions at Cognate Bioservices
- Cell Therapy Business Development Leader at Invitrogen
- Jobs at Geron: chemists, process and product development, cell biology, immunology, assay development, and quality positions
- Manufacturing Manager at Cognate Bioservices
- Process Dev, R&D, Quality and other jobs at Tigenix (Belgium and US)
- RegenMed Scientists and Research Associates at Athersys
- Research and Quality positions at Biomimetic Therapeutics
General Science
Local Biotech Gateways
Other Biotech Blogs
Patents
Archives
Catagory Cloud
adult stem cell Advanced Cell Technology Apptec Athersys BD Big Pharma Biomaterials Bioprocessing business models cardiac regeneration cell delivery Clinical Trials combination products Company Profiles Embyonic Stem Cells FDA Geron Innovation Intellectual Property Invitrogen JNJ Job search Joint Ventures Manufacturing Novocell Osiris Regenerative Medicine regulatory stem cells vascular regeneration
Category Archives: Regenerative Medicine
Takin’ a short blog break
Currently, I am in the middle of moving my family to Frederick, Maryland. I am starting a new position at Lonza, and it may take a couple weeks to figure out how the blog fits with the new position/company. Please … Continue reading
Q Therapeutics’ and Invitrogen’s Symbiotic Relationship
Q Therapeutics, a cell therapy company focusing on neural applications, recently announced a $15M series B financing that included funding from multiple venture capital (VC) groups as well as biotech tools provider Invitrogen. Q’s lead product, Q-Cells™, is an allogeneic … Continue reading
The Developing Embyronic Stem Cell Clinical Landscape
ES cell biopsy from blastocyst. Continue reading
Posted in adult stem cell, Advanced Cell Technology, Athersys, Clinical Trials, Cytori, Embyonic Stem Cells, FDA, Geron, JNJ, Novocell, Osiris, Regenerative Medicine, spinal cord injury, stem cells
Tagged Clinical Trials, embryonic vs adult stem cell, embyryonic stem cell 2008, evolving clinical landscape, safety issues
Leave a comment
Geron Bolsters Extensive Embryonic Stem Cell Patent Estate
Geron yesterday announced the issuance of US patent #7,326,572, helping to extend their patent protection around their embryonic stem (ES) cell platform technology in the area of treating type 1 diabetes. Currently, Geron owns an exclusive license from the Wisconsin … Continue reading
Cytori Announces Progress in Cardiac Regeneration Clinical Studies
Cytori Therapeutics announced that they have enrolled their first two patients in an acute myocardial infarction clinical trial using adipose-derived cells prepared using their Celution™ device. The Celution™ device is an automated, tissue processing unit that isolates cells from adipose … Continue reading
The Regenerative Medicine Job Search: The Interview
by Susan Hsiong, PhD You’ve been submitting resumes like nobody’s business. And contacted everyone you know asking if they know of any job opportunities. You’ve attended all the local networking events and career fairs. After what seems like forever, you … Continue reading
Posted in Job search, Regenerative Medicine
Tagged interview questions, interviewing, job hunting, Job search
7 Comments
Tengion Pioneers Autologous Tissue Engineered Regenerative Medicine Products
You have to hand it to Tengion, they are trying to tackle one of the largest challenges I can think of: producing tissue engineered organs and tissues from a patients own cells in unrelated indications (bladder, blood vessel, and kidney). … Continue reading
Posted in autologous, Biomaterials, Bioprocessing, Clinical Trials, combination products, Company Profiles, JNJ, patient specific cell therapy, personalized medicine, Regenerative Medicine, Tengion, tissue engineered product, vascular regeneration
Tagged autologous therapies, company prifile, tissue engineering company
3 Comments
The Job Search: Large vs. Small Companies – pros and cons
Here is another take on working in a big company from ScienceMag (http://sciencecareers.sciencemag.org/career_development/tools_resources/forum/view?id=3845) Continue reading
Posted in Job search, Regenerative Medicine
Tagged big vs small companies, Job search, pros and cons
8 Comments
Pervasis Advances Tissue Engineered Products for Vascular Health
Pervasis Therapeutics announced that they have raised $9.75M to further develop their allogenic tissue engineered endothelial cell (EC) product for vascular health indications. Their Vascugel product is comprised of ECs grown in 3D collagen sponges that are implanted externally on … Continue reading
Posted in Biomaterials, Bioprocessing, cell delivery, Clinical Trials, combination products, Company Profiles, Manufacturing, Pervasis, Regenerative Medicine, tissue engineered product, vascular regeneration
Tagged end stage renal disease, endothelial cells, ESRD, gelfoam, tissue engineering, vascular health
1 Comment
Mimetic Solutions Pioneers New Smart Biomaterials for Controlled Release
When we have a cold or a headache, we pop a pill. We get sick, we go to the doctor and get a shot. Taking medication orally via a pill or getting drugs injected via a syringe are some of … Continue reading
Osiris Scores $225M DoD Contract for Acute Radiation Syndrome Treatment with Prochymal Adult Stem Cell Product
Osiris Therapeutics announced that they won a DoD contract worth up to $224.7 million for developing their adult mesenchymal stem cell (MSC)-based therapeutic for treating acute radiation exposure. The contract allows for reimbursement of up to $24.7 million for continued … Continue reading
China and the Regenerative Medicine Industry
Just a quick note on a topic that keeps catching my attention: China. Three interesting things have come up in the last month: Organogenesis signs a distribution deal with China’s National Tissue Engineering Center, with the potential to expand into … Continue reading
Posted in Regenerative Medicine
1 Comment
Consolidation Trends Within the Blossoming RegenMed Service Sector
The WuXi acquisition of Apptec (posted last week) is continuing the trend of consolidation in the cell manufacturing sector. It is similar to Lonza’s (a Swiss company) purchase of Cambrex’s biologics division in 2006, and GE’s purchase of Wave Biotech … Continue reading
Biomimetics Therapeutics Expands into New Markets with Innovative GEM OS Combination Device
by Susan Hsiong, PhD Biomimetics Therapeutics, Inc. (Franklin, TN), a company which develops drug-device combination products for orthopedic applications, recently announced positive results from its Canadian clinical study evaluating its GEM OS®1 Bone Graft for the open surgical treatment of … Continue reading
Posted in Biomaterials, biomimetics therapeutics, bone regeneration, combination products, Company Profiles, controlled release, Medtronic, Regenerative Medicine
Tagged biomimetics therapeutics, bone graft substitutes, bone healing, combination products, controlled release, GEM OS1, Infuse, orthopedics, recombinant protein products
3 Comments
Chinese CRO WuXi Pharmatech Acquires Apptec Laboratory Services
WuXi (pronounced Woo-See) Pharmatech, a contract research organization (CRO) based in China, announced the acquisition of MN-based Apptec Laboratory Services. WuXi acquired Apptec to gain an immediate US footprint, better access to the US market, and important biologics expertise to … Continue reading
Celgene Strengthens Adult Stem Cell Patent Estate
I have recently signed up for the StemCellPatents.com weekly newsletter, and it is great to keep updated on all the patents that get issued in regenerative medicine. In the most recent newletter, they reported on two patents that issued last … Continue reading
New Year’s Resolutions for the Regenerative Medicine Industry
With the New Year upon us, I thought it would be good to make a set of New Year’s Resolutions for the regenerative medicine industry. This set of resolutions is not company specific, but things that will be required to … Continue reading
FDA Proactively Addresses Embryonic Stem Cell Safety Testing
The FDA has scheduled an April 10, 2008 meeting to “discuss scientific considerations for safety testing for cellular therapy products derived from human embryonic stem cells.” This meeting will be followed by another meeting on April 11 that will “discuss … Continue reading
Top Ten Events in the Regenerative Medicine Industry in 2007
Top Ten Events in the Regenerative Medicine Industry in 2007 (according to Jon Rowley, and in no particular order): Embyronic stem cells were primed for human trials. Both Advanced Cell Technology and Geron are gearing up for INDs in early … Continue reading
Posted in Regenerative Medicine
1 Comment
Athersys’ Adult Stem Cell Product IND Approved for Acute MI Phase I Trial
Athersys and their cardiac parter, Angiotech, announced today that they got the ok from the FDA to begin a Phase I clinical study using Athersys’ Multistem adult stem cell product in acute myocardial infarction (MI). This is the second IND … Continue reading
The Regenerative Medicine Industry Job Search – Resources and Advice
A guest post by Susan Hsiong, PhD You worked hard as a lab rat for the past several years and you’re eager to move on to the next step. However, the transition from academia to industry is a tricky one. … Continue reading
BioTime Births Embryome Sciences
There have been some interesting news releases this week, including Osiris’ fast track designation, Cytori obtaining a 510k for their fat cleaner (not their stem cell isolation device, just a clinical fat cleaner), and the angiogenesis and liver regeneration capabilities … Continue reading
Organogenesis Expands into China
Organogenesis, one of the pioneering tissue engineering companies, is partnering with China’s National Tissue Engineering Center (NTEC) to bring Organogenesis’ regenerative therapies to the Chinese marketplace. NTEC is a Shanghai-based private company that is funded by the Chinese government, and … Continue reading
Jobs in Regenerative Medicine: Part I
One of the aspects of my science career that I really enjoy is the career coaching that I provide, and receive. I actually spend a lot of time telling students that are graduating, whether it is at the Bachelors, Masters, … Continue reading
Biomaterials as Therapies
The regenerative medicine industry is banking on cellular therapy to help regenerate tissues and restore function in clinical indications with high unmet needs. The mechanism of action, or how stem cells actually drive tissue regeneration, is still hotly debated – … Continue reading
Patent Reform Act of 2007 – Impact on Regenerative Medicine
The author of CELLWISE, one of the newer bio-Blogs out there, asked a question related to the Patent Reform Act of 2007 in a comment on the Pfizer post. He asked: The article that is cited is right; our patent … Continue reading
Osiris Releases 1 Year Data from Chrondrogen Trial
Osiris Therapeutics last week announced positive data that came out of their Phase I/II double blinded Chondrogen trial. They demonstrated statistically significant improvements in joint pain in patients with osteoarthritis, however this seems to be an about face compared to … Continue reading
CellCyte Issued Patent for Enhancing Cell Delivery to Cardiac Tissue
CellCyte Genetics Corporation recently announced that US Patent No 7,282,222 was issued, a patent which they have exclusive rights to. The press release states that the patent covers unique methods and compositions “to deliver and direct stem cells to target … Continue reading
Embryonic Stem Cells without Embryos: big scientific impact, but doesn’t change industry direction
I do not want to undermine the importance of the great work that was done in generating pluripotent stem cells from adult skin cells, but the only thing I think about when hearing this news is TIME and MONEY. I … Continue reading
Posted in Regenerative Medicine, stem cells
2 Comments
Athersys’ adult allogeneic stem cell IND gets OK from FDA
On November 15, 2007, Athersys announced in a press release that they had received a letter from the FDA giving the green light to start a Phase I safety study of MultiStem, their adult, allogeneic stem cell product. Athersys will … Continue reading
Posted in adult stem cell, Athersys, Clinical Trials, FDA, MSCs, Osiris, Regenerative Medicine, stem cells
Tagged adult stem cells, Athersys, business model, stem cells clinical trials
1 Comment
Geron publishes data suggesting that Embyonic Stem Cells may not need long term immunosuppression
An interesting study was published this week in the Journal of Neuroimmunology spurring a press release from Geron that stated “GERON’S HUMAN EMBRYONIC STEM (ES) CELL-BASED THERAPEUTIC FOR SPINAL CORD INJURY EVADES DIRECT ATTACK BY THE HUMAN IMMUNE SYSTEM”. The … Continue reading
Inaugural Post @ The Regeneration Station
I am not sure if you noticed, but the stem cell stocks haven’t been performing all that great in 2007, especially compared to technology companies like Apple or Google. So now seems as good a time as any to start … Continue reading
Posted in Regenerative Medicine, Uncategorized
Tagged regenerative medicine 2.0, stem cells
1 Comment
The Regeneration Station 